mRNA Vaccines for Flu
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza virus).
This study is seeking healthy participants 18 years of age or older. All participants in this study will receive only 1 dose in their arm, to deliver one of the experimental flu vaccines or one of the approved flu vaccines used for comparison.
Participants will take part in this study for about 6 months, and participants will need to visit the study site at least 3 times. A blood sample will be taken at each of the 3 planned study visits and a swab from inside the nose will be taken at the first study visit.
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of either an experimental mRNA influenza vaccine or a licensed influenza vaccine via intramuscular injection
Follow-up
Participants are monitored for safety and immunogenicity, with blood samples taken at each visit
What Are the Treatments Tested in This Trial?
Interventions
- Vaccine Candidate #1
- Vaccine Candidate #2
- Vaccine Candidate #3
- Vaccine Candidate #4
- Vaccine Candidate #5
- Vaccine Candidate #6
How Is the Trial Designed?
7
Treatment groups
Experimental Treatment
Active Control
mRNA influenza vaccine candidate #6 as a single IM injection on Day 1.
mRNA influenza vaccine candidate #5 as a single IM injection on Day 1.
mRNA influenza vaccine candidate #4 as a single IM injection on Day 1.
mRNA influenza vaccine candidate #3 as a single IM injection on Day 1.
mRNA influenza vaccine candidate #2 as a single IM injection on Day 1.
mRNA influenza vaccine candidate #1 as a single intramuscular (IM) injection on Day 1.
Licensed influenza vaccine (TIV1 or TIV2) as a single IM injection.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.